AD/PD 2015: Fosters Debate, Discussion and Collaboration
Cutting edge scientific breakthroughs presented at AD/PD 2015 included emerging technologies for manipulating the immune response to treat neurological diseases, novel molecular brain imaging technologies and biomarkers of disease.
Geneva, Switzerland, March 22, 2015 – Kenes Group, a leading Professional Conference Organiser (PCO) and Association Management Company (AMC), today announced the first reports from AD/PD 2015, praising the event’s unequivocal success, delving into powerful insights of the world’s latest research, developments, and treatments. Renowned for its broad, multidisciplinary approach, AD/PD 2015 was aimed at clinical investigators and basic scientists, established investigators as well as young upcoming talents. The stimulating academic programme combined with a collegial environment was hailed as “fostering debate, discussion and collaboration.”
The 12th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD 2015, was built on the well-earned reputation of previous AD/PD meetings for unraveling the mechanisms and improving the treatment of Alzheimer’s, Parkinson’s and other related neurodegenerative diseases. Participants reported on the exceptionally stimulating academic programme matched with the meeting’s collegial environment – “fostering debate, discussion and collaboration” among delegates, speakers and exhibitors.
The world’s neurodegenerative disease specialists gathered March 18-22, 2015 in Nice, France at AD/PD 2015, co-organized by Abraham Fisher, Roger Nitsch and Manfred Windisch, is a landmark event bringing together over 3,000, neuroscientists, pharmacologists and clinicians to study the hot topics, similarities and differences and scientific breakthroughs associated with Alzheimer’s Disease, Parkinson’s Disease and related neurological disorders, and to evaluate advances that might ameliorate many of these diseases.
Speakers included Nobel Prize Laureates Elizabeth Blackburn, Tom Südhoff and Ada Yonath, as well as a large faculty of the world’s premier experts in neuroscience and brain diseases complemented by a vibrant community of young emerging investigators who are on their ways to shape the future of this field.
Cutting edge scientific breakthroughs presented at AD/PD 2015 included emerging technologies for manipulating the immune response to treat neurological diseases, novel molecular brain imaging technologies and biomarkers of disease. New insights into disease mechanisms include seeding and spreading of misfolded proteins, as well as epigenetic and genetic effects in neurodegenerative diseases. The role of receptors and enzymes as potential novel therapeutic targets were also discussed.
“AD/PD combines all the neurodegenerative diseases under one roof,” said Dr. Abraham Fisher, the President of AD/PD 2015.”It is the main platform for the world’s experts to present their latest findings and research in diagnosis, prevention and discovery of new treatment targets for these debilitating disorders.”
The multidisciplinary scientific programme consisted of the three main tracks “Treatment Strategies”, “Basic Science” and “Clinical Studies”. Major sessions were devoted to clinical aspects in Alzheimer’s disease, Parkinson’s disease and related brain diseases. A Podium Discussion assessed if standardization can improve the predictive value of animal models. The meeting concluded with a Podium Discussion by world renowned experts exploring strategies to mitigate the high attrition rate in current drug development in order to shape the future of clinical practice with disease-modifying drugs.
Neurodegenerative diseases are a serious health challenge facing all societies with ageing demographics. Founded in 1985 by Abraham Fisher and Israel Hanin, AD/PD conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their integration. AD/PD is now the world’s foremost platform devoted to promoting the latest advances in neurodegenerative disease research and new therapies.
For more information, contact:
Marketing Communications Manager